The area of drug discovery tools is one of the newest and most important sectors of pharmaceutical research and development. The term drug discovery tools usually refers to high-content screening (HCS) and analysis and is composed of those applications that require sufficient levels of sample throughput, whereby complex cellular events and phenotypes can be studied. Elements of drug performance like toxicity and specificity can be established simultaneously using mixed cell types-primary cells, cell lines, cell subpopulations. HCS seeks to assess the impact of phenotypic and cellular changes that are brought about by gene modification (such as with RNA interference (RNAi) approaches) and/or drug (or compound) treatment. The purpose of this examination by TriMark Publications is to describe the specific segments of the global drug discovery tools market. Within this area, the report covers those segments that are highly active in terms of innovation and growth. Specifically, this study examines the markets for small lab equipment all the way up to highly automated, large automated platforms, as well as accessory equipment such as reagents, supplies and manufacturers' original equipment manufacturer (OEM) additional equipment.
Table of Contents
1.Overview4
1.1Objectives of the Report4
1.2Methodology5
1.3Scope of the Report6
1.4Executive Summary7
2.Technologies and Product Offering for HCA10
2.1Definition of HCA and Why it is so Attractive a Discipline11
2.2Classes of Measurements Possible with HCA Approaches and Biologies Interrogated14
2.3Instrumentation Platforms for HCA17
2.4Reagent and Assay Platforms for HCA23
2.5Cell-based Screening Technologies in Drug Development27
2.5.1Applications of Cell-based Assays27
2.5.2Pharma Drug Discovery Paradigm and Compound Screening27
2.5.3HCA in the Biopharmaceutical Industry28
3.Market Analysis of the High-Content Tools Space30
3.1HCA Market Size and Growth30
3.2Market Survey to Assess Qualitative and Quantitative Parameters of the HCA Space30
3.3Experimental and Research Trends in HCA32
3.4Challenges and Market Drivers in HCA37
3.4.1Barriers to HCA39
3.4.2Drivers of HCA40
3.5HCA in Combination with RNAi40
3.6Market Landscape of Instrumentation for HCA42
3.7Reagents and Assays Usage in HCA45
3.8Trends in HCA Assays/Reagents Space-Major Product Vendors49
3.9Emerging Market Trends in HCA51
3.10Market Forecasts for the HCA Space53
3.11Use of HCS in Pharmaceutical Companies55
3.12Qualitative Opportunities and Challenges for Market Adoption56
4.Strategic Analysis of the High-Content Tools Space57
4.1HCA Market Structure57
4.2Description of the Drug Discovery Marketplace and Definition of the Field57
4.3Key Market Drivers and Challenges in the HCA Space58
Figure 3.7: Breakout of HCA Assays Currently Performed or Expected to be Performed in the Future by Biological Pathway (or Target)35
Figure 3.8: Breakout of HCA Experiments Performed Per Week (Distributed in our Respondent Pool) Across the Various Biological Pathways (and Targets)35
Figure 3.9: Which of the Biologies (Pathways/Targets) Addressed Using HCA-based Approaches are Growing in Importance or Declining?36
Figure 3.10: In Which Environment are HCA Assays Performed-Primary Screen, Secondary Screen, ADME/Tox Screen?37
Figure 3.11: Key Challenges Faced by the Research Community in Their Practice of HCA38
Figure 3.12: Various Drivers that are Leading the Research Community to Perform HCA39
Figure 3.13: HCA Together with RNAi-Current and Future Experimental Formats40
Figure 3.14: HCA Together with RNAi-Number of Experiments Performed Per Month by the Survey Respondent Pool41
Figure 3.15: Growing and Steady Usage of the Various Formats where RNAi is coupled with HCA41
Figure 3.16: Penetration of the Different HCA Instrumentation Platforms into the Marketplace43
Figure 3.17: Instrumentation Platforms for HCA Ranked by Top Choice and Second Tier43
Figure 3.18: HCA Instrumentation and where they lie on the Throughput Curve44
Figure 3.19: Top Instrumentation Value Drivers in the HCA Space45
Figure 3.20: Important Sub-Cellular Features Studied via HCA Approaches46
Figure 3.21: Breakout of End-Point versus Kinetic Assays in the HCA Space46
Figure 3.22: Types of Cellular Targets Studied Using HCA Approaches47
Figure 3.23: Top-most Target Class Being Studied Utilizing HCA Approaches47
Figure 3.24: Distribution of HCA Experiments across the Respondent Pool-Number of Experiments Performed Per Week48
Figure 3.25: Average Reagent/Assay Costs Per HCA Experiment48
Figure 3.26: Stratification of Reagent/Assay Suppliers into the HCA Space49
Figure 3.27: Monthly Reagent/Assay Purchases for HCA by the End-User Community from the Various Vendors Offering Products into the Space50
Figure 3.28: Growth or Decline in Importance of the Various HCA Vendors to the End-User Community51
Figure 3.29: Percentage of HCA Experiments that Involve GFP across the Market Landscape52
Figure 3.30: Breakout of HCA Reagents Marketplace: Home-Brew Versus Off-the-Shelf52
Figure 3.31: Breakout of Spending into the Various Components of the HCA Discipline53
Figure 3.32: Forecast Growth of the Total Screening Space-Broken-out by Primary Screening, Secondary Screening (Includes HCA as a Subset) and ADME/Tox54
Figure 3.33: Forecast Growth of the Screening Space-Broken-out by Cell-based Assays and Biochemical Assays55
Figure 4.1: Drug Discovery and Development Ensemble and the Position of the Various Segments of HCA in the Space60
Figure 4.2: Relative Size and Position of the HCA Space in the Overall Scheme of the Life Science Tools Marketplace62
Figure 5.1: HCA: Positional Biosensors Using Caspases and Monitoring the Translocation of a Tagged Protein from the Cytoplasm to the Nucleus67
Figure 6.1: Druggability of the Various Target Classes: Breakout of the Drug Targets Today into their Constituent Classes70
Figure 6.2: GPCR Assay Technologies71
LIST OF TABLES
Table 2.1: Comparison of the Key Features of HCA and HCS11
Table 2.2: Impact of HCA on Drug Discovery-Several Drivers are Addressed12
Table 2.3: Biological Application Areas Associated with HCA13
Table 2.4: Classes of Measurements and Targets Identified Using Phenotypic Screening (HCA)14
Table 2.5: Classes of Cellular Measurements Possible with Fluorescent Protein Biosensors15
Table 2.6: Multi-Parameter HCA Assays to Study Biological Systems in Life Science Research and Drug Discovery-Demonstrates the Breadth and Scalability of the HCA Approach17
Table 2.7: Companies Offering Systems for High-Throughput Imaging18
Table 2.8: Comparison of the Major Instrumentation Platforms and their Associated Specifications for HCA-I19
Table 2.9: Comparison of the Major Instrumentation Platforms and their Associated Specifications for HCA-II19
Table 2.10: Price Points and Target Markets of the Various HCA Instrument Platforms20
Table 2.11: Companies Offering Flow Cytometry Products and Services20
Table 2.12: Integrated Product Platforms Offered by the Different HCA Vendors22
Table 2.13: Biologies interrogated by Cellomics HCA Assays24
Table 2.14: Cellomics HitKit® HCA Assay/Reagent Kits and the Therapeutic Areas Where They Find Application24
Table 2.15: Assay/Reagent Portfolio of Millipore Addressing HCA Applications25
Table 2.16: Cell Lines for GPCR HCA that can be Deployed onto the BD Biosciences/Atto Pathway HT™ Instrument Platform26
Table 2.17: Examples of High Content Screens28
Table 3.1: What Fraction of HCA Assays are Cell-based Versus Biochemical-based32
Table 4.1: Comparison of the Key Features of HCA and HCS58
Table 4.2: Snapshot of the Various HCA Assays Demonstrating the Scalability of this Discipline60
Table 5.1: Modes of Digital Imaging64
Table 5.2: Modes of Fluorescence64
Table 5.3: Major HCA Instrumentation65
Table 5.4: Image Analysis Algorithms67
Other users found this report page using the following search terms:
drug discoveryhcaassays
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
